A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis

ATP‐binding cassette (ABC) transporter expression and genetic heterogeneity have been implicated in response to anticancer therapy. This study characterized genetic variability of the ABCB1 (also known as MDR1), ABCC2 (MRP2) and ABCG2 (BCRP) genes, which are key players in the metabolism of many chemotherapeutic agents including those used in the treatment of lung cancer. We genotyped 53 polymorphisms in the candidate genes in genomic DNA samples of 171 cases of small cell lung carcinoma (SCLC) and 206 cases of non‐small cell lung carcinoma (NSCLC), and studied their impact on early response to chemotherapy, progression‐free survival and overall survival. SNP rs717620 in ABCC2 was moderately associated with a poor response to chemotherapy but strongly with shorter progression‐free survival and overall survival in SCLC but not NSCLC patients, indicating that ABCC2 genetic variation is an important factor in SCLC survival after chemotherapy.

[1]  I. Cascorbi,et al.  Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function , 2011, The Pharmacogenomics Journal.

[2]  V. Pankratz,et al.  Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  Honghao Zhou,et al.  MDR1 C2005T polymorphism changes substrate specificity , 2010, Cancer Chemotherapy and Pharmacology.

[4]  Yusuke Nakamura,et al.  Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Lee,et al.  A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy , 2010, Pharmacogenetics and genomics.

[6]  W. Figg,et al.  Pharmacogenetics of Membrane Transporters: An Update on Current Approaches , 2010, Molecular biotechnology.

[7]  J. Beijnen,et al.  P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide , 2009, Clinical Cancer Research.

[8]  Bowang Chen,et al.  SNP_tools: A compact tool package for analysis and conversion of genotype data for MS-Excel , 2009, BMC Research Notes.

[9]  H. Bartsch,et al.  Polymorphisms in ABCG2, ABCC3 and CNT1 genes and their possible impact on chemotherapy outcome of lung cancer patients , 2009, International journal of cancer.

[10]  Eden R Martin,et al.  A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms , 2008, Genetic epidemiology.

[11]  Yusuke Nakamura,et al.  Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel‐induced leukopenia , 2008, Cancer science.

[12]  A. Caliebe,et al.  Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol , 2008, Pharmacogenetics and genomics.

[13]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[14]  E. Shin,et al.  Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Y. Sugimoto,et al.  Functional SNPs of the breast cancer resistance protein-therapeutic effects and inhibitor development. , 2006, Cancer letters.

[16]  Su Jung Lee,et al.  MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. , 2006, Japanese journal of clinical oncology.

[17]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[18]  J. Schuetz,et al.  Role of ABCG2/BCRP in biology and medicine. , 2006, Annual review of pharmacology and toxicology.

[19]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[20]  J. Li,et al.  Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix , 2005, Heredity.

[21]  M. Volm,et al.  Pharmacogenetics for individualized cancer chemotherapy. , 2005, Pharmacology & therapeutics.

[22]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[23]  H. Kotani,et al.  Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2 , 2004, International journal of cancer.

[24]  Y. Nishiwaki,et al.  Breast Cancer Resistance Protein Impacts Clinical Outcome in Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[25]  J. Coebergh,et al.  The changing epidemiology of lung cancer in Europe. , 2003, Lung cancer.

[26]  E. Brambilla,et al.  p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice , 2003, Oncogene.

[27]  Y. Sugiyama,et al.  Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. , 2002, Advanced drug delivery reviews.

[28]  F. Kaye,et al.  RB and cyclin dependent kinase pathways: defining a distinction between RB and p16 loss in lung cancer , 2002, Oncogene.

[29]  G. Sandusky,et al.  Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays , 2002, Histopathology.

[30]  Y. Miki,et al.  C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. , 2002, Molecular cancer therapeutics.

[31]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[32]  D. Postma,et al.  Multidrug resistance related molecules in human and murine lung. , 2002, Journal of clinical pathology.

[33]  Y. Yatabe,et al.  Frequent and histological type-specific inactivation of 14-3-3σ in human lung cancers , 2002, Oncogene.

[34]  E. Brambilla,et al.  Distinct pattern of E2F1 expression in human lung tumours: E2F1 is upregulated in small cell lung carcinoma , 2001, Oncogene.

[35]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[36]  M. Minemura,et al.  Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines. , 1999, International journal of oncology.

[37]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[38]  I. Wistuba,et al.  Genetic changes in the spectrum of neuroendocrine lung tumors , 1999, Cancer.

[39]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[40]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[41]  O. Fardel,et al.  The P-glycoprotein multidrug transporter. , 1996, General pharmacology.

[42]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[43]  Europe.,et al.  In Europe … , 1994, Current History.

[44]  S. Rodenhuis,et al.  Clinical significance of ras oncogene activation in human lung cancer. , 1992, Cancer research.

[45]  I. Cascorbi,et al.  Pharmacogenetics of ATP-binding cassette transporters and clinical implications. , 2010, Methods in molecular biology.

[46]  H. Kroemer,et al.  Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex , 2007, The Pharmacogenomics Journal.

[47]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.